In the ongoing battle against treating and healing wounds and infectious skin diseases, ViaDerma stands at the forefront of innovation, developing and licensing the world’s most potent broad-spectrum antibiotics. Founded in 2014 by Dr. Christopher Otiko, ViaDerma Inc. (VDRM) has revolutionized the healthcare industry with its patent-pending dual carrier transdermal delivery technology, turning oral medications into topical ointments that deliver rapid results for patients.
Their lead product, Vitastem Ultra, is a testament to the power of this advanced transdermal delivery system, showcasing impressive efficacy in treating a wide range of infectious diseases.
In this exclusive interview, we delve into the origins of ViaDerma, the company’s groundbreaking technology, and how their products are set to disrupt the healthcare industry.
Dr. Otiko shares his educational background and the inspiration behind ViaDerma, while also discussing the unique benefits of their topical delivery system, the safety of their products, and their potential to combat healthcare-associated infections (HAIs) that lead to MRSA and staph infections.
Interview with Dr. Christopher Otiko, CEO at ViaDerma
How did ViaDerma get started?
I wanted to start a company that could produce medication to save a lot of lives. ViaDerma was founded back in 2014. Since our inception, we’ve gone on to create one of (if not) the world’s strongest first aid & topical antibiotics, Vitastem Ultra. It was originally created to treat diabetic foot wounds and prevent amputations. So far, Vitastem has been used to save countless amputations due to diabetic wounds.
Where did you go to medical school?
I received my BS in Biochemistry at Ilorin University in Ilorin, Nigeria. After that, I got my master’s degree in Biochemistry at Oklahoma State University. Then, I attended what was then called the California College of Podiatric Medicine in San Francisco, CA where I obtained my Doctor of Podiatric Medicine degree.
What makes your topical delivery system so special for health care?
ViaDerma uses a patent-pending, specialized combination of ingredients which has basically hacked the delivery formula that enables medicine to be transported at 10x the strength and depth of other competing products available today. This can be seen particularly well with the use of our lead product Vitastem Ultra, a new FDA-registered topical antibiotic & first aid.
Our proprietary formula stimulates one’s cell wall in such a way that it is up to 10x more permeable than normal. This process allows substantially more medicine to enter the cell, which then overwhelms and kills the bacteria so quickly that it doesn’t have enough time to adapt and develop any resistance. This process of rapidly delivering highly concentrated doses of medicine to the site of treatment is why patients will often see results within 24 hours, compared to 5 to 7 days (or longer) when using competing products to treat the same condition(s).
How safe are your topical antibiotic products?
Our lead product Vitastem Ultra is safe for all age groups. Vitastem falls under a “CLASS I MEDICAL PRODUCT” which means it’s among the safest categories of medical products available. Vitastem Ultra is FDA-Registered and available for over the counter (OTC) use. Our new hair regrowth product is in the process of getting FDA-Registered too. Furthermore, unlike oral antibiotics, Vitastem is a topical antibiotic, and it will not harm the patient’s kidneys or any of the good bacteria in their stomach.
How can ViaDerma disrupt the healthcare industry?
Our intention is to add a lot of value to healthcare professionals and their patients by providing best-in-class technology and products to treat wounds, skin diseases & conditions more effectively than other products currently available.
A big focus will be to help hospitals, surgery centers, and nursing homes drastically reduce if not eradicate MRSA & staph infections caused by HAIs (healthcare associated infections). Unfortunately, these are a significant cause of illness and death, while often causing additional emotional, financial, and medical consequences too. At any given time in the US alone, there’s nearly 1 in 30 inpatients that have an infection related to hospital care. According to the CDC, in American hospitals alone, HAIs account for an estimated 1.7 million infections and about 99,000 deaths associated with them each year.
Many of these cases can be prevented and we strongly believe our lead product Vitastem Ultra is a solution to this growing issue. Vitastem Ultra is the only antibiotic in the world that kills with both a physical and chemical mechanism, this gives our solution a very unique ability to defeat drug resistant bacteria. Furthermore, Vitastem Ultra has successfully killed all known bacteria it has ever been tested against, including common antibiotic-resistant MRSA (flesh-eating bacteria) and Staph Infection.
To date, Vitastem has helped save countless patients from amputations, while helping to reduce their hospital stays and increase their life expectancy too.
Transforming Healthcare with ViaDerma
ViaDerma is a game-changing force in the healthcare industry, with its innovative dual carrier transdermal delivery technology revolutionizing the way that we as a society will approach infectious skin diseases and wound care.
Their lead product, Vitastem Ultra, demonstrates the immense potential of this technology to improve patients’ lives and disrupt traditional treatment methods. The company’s commitment to providing best-in-class products and addressing major healthcare challenges such as HAIs further underscores its dedication to driving positive change.
Dr. Otiko’s passion for saving lives and his impressive educational background have shaped ViaDerma into a disruptive pharmaceutical company. As the industry continues to evolve, ViaDerma’s unique and innovative solutions offer a promising path towards more effective, efficient, and safer wound and skin care treatments.
By targeting some of the most pressing issues in healthcare today, such as the big rise in HAIs (healthcare-acquired infections) like staph & MRSA, ViaDerma is poised to make a lasting impact on both patients and healthcare professionals alike, solidifying its position as a leader in the field of transdermal drug delivery, skin condition treatments, and wound care.